Physician profile
Mona S Foad
NPI 1316011661
$212,491.63
in general payments reported to CMS, 2019-2025
25 companies · $50K in 2025
The $50K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,354 · 2020: $522 · 2021: $33K · 2022: $19K · 2023: $55K · 2024: $53K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $124K · Travel and Lodging: $16K · Consulting Fee: $9,798 · Food and Beverage: $8,665 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124,090.40 |
| Travel and Lodging | $15,503.75 |
| Consulting Fee | $9,797.67 |
| Food and Beverage | $8,664.67 |
| Education | $174.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $155,602.02 | 2019-2025 | |
| Allergan, INC. | $54,098.91 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $555.41 | 2019-2025 | |
| Pfizer INC. | $357.09 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $304.12 | 2021-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $281.75 | 2022-2024 | Sotyktu |
| Janssen Biotech, INC. | $211.62 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Galderma Laboratories, L.P. | $148.89 | 2019-2025 | Dysport |
| Ucb, INC. | $132.34 | 2019-2025 | Bimzelx |
| Merz North America, INC. | $128.02 | 2019-2024 | |
| Incyte Corporation | $89.61 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $87.58 | 2019-2025 | Anzupgo |
| Lilly USA, LLC | $84.77 | 2019-2024 | Taltz, Olumiant |
| Vyne Pharmaceuticals INC. | $78.73 | 2020 | |
| Celgene Corporation | $47.80 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $46.72 | 2023-2025 | Zoryve |
| Genzyme Corporation | $46.70 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $42.11 | 2019-2023 | |
| Biofrontera INC. | $33.30 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Strata Skin Sciences, INC. | $24.10 | 2025 | Xtrac |
| Verrica Pharmaceuticals INC. | $22.09 | 2024 | Ycanth |
| Dermira, INC. | $20.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.51 | 2019 | |
| Almirall LLC | $14.41 | 2024 | Klisyri |
| Amgen INC. | $14.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Foad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.